VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib

BACKGROUND: Currently, sunitinib represents one of the therapeutic strongholds for renal cell carcinoma, but the criteria for treatment selection are lacking. We assessed the role of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) polymorphisms in the prediction of the clinical o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Scartozzi, M, Bianconi, M, Faloppi, L, Loretelli, C, Bittoni, A, Del Prete, M, Giampieri, R, Maccaroni, E, Nicoletti, S, Burattini, L, Minardi, D, Muzzonigro, G, Montironi, R, Cascinu, S
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2013
Assuntos:
Molecular Diagnostics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3619056/
https://ncbi.nlm.nih.gov/pubmed/23511629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.501
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares